Literature DB >> 3790585

Membrane lipid changes in erythrocytes, liver and kidney in acute and chronic experimental liver disease in rats.

S Kawata, A Chitranukroh, J S Owen, N McIntyre.   

Abstract

Lipid molecules in lipoprotein surfaces exchange with their counterparts in cell plasma membranes. In human or experimental liver disease, plasma lipoprotein surfaces are enriched in cholesterol and deficient in arachidonate; corresponding alterations occur in membrane lipids of erythrocytes. To determine whether similar changes take place in membranes of nucleated cells, the lipid content of plasma and of erythrocyte, liver and kidney membranes was measured in rats with acute (3-day) galactosamine-induced hepatitis or chronic (3-week) biliary obstruction. In both models of liver injury the cholesterol:phospholipid ratio in plasma and in erythrocytes was significantly increased (P less than 0.001). Although this ratio was also elevated in liver and kidney microsomes, only in liver microsomes of obstructed rats was the increase significant (P less than 0.001). However, the cholesterol:phospholipid ratio of kidney brush-border membranes, was significantly higher in bile-duct-ligated rats; presumably, compensating mechanisms limit cholesterol accumulation in intracellular membranes. Kidney brush-border membranes from obstructed rats were deficient in arachidonate as were plasma and erythrocytes. However, arachidonate levels were unchanged in kidney microsomes; renal delta 6-desaturase, the rate-limiting enzyme in the conversion of linoleic acid to arachidonic acid, was increased by 50% (P less than 0.001) and may have counteracted a reduced supply of exogenous lipoprotein arachidonate. We conclude that in experimental liver disease lipoprotein-induced lipid abnormalities can occur in renal membranes, although compensatory mechanisms may operate; the alterations seen, cholesterol accumulation and arachidonate depletion, would be expected to interfere with sodium transport and prostaglandin production, respectively. Our findings support the hypothesis that lipid abnormalities in kidney membranes contribute to the renal dysfunction which is a frequent complication of human liver disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3790585     DOI: 10.1016/0005-2736(87)90352-x

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  10 in total

1.  Changes in lipid composition of erythrocyte membranes with administration of S-adenosyl-L-methionine in chronic liver disease.

Authors:  H Kakimoto; S Kawata; Y Imai; M Inada; Y Matsuzawa; S Tarui
Journal:  Gastroenterol Jpn       Date:  1992-08

Review 2.  Extrahepatic cell membrane lipid abnormalities and cellular dysfunction in liver disease.

Authors:  J S Owen
Journal:  Drugs       Date:  1990       Impact factor: 9.546

3.  Ursodeoxycholic acid suppresses extent of lipid peroxidation in diseased liver in experimental cholestatic liver disease.

Authors:  P Ljubuncic; Z Tanne; A Bomzon
Journal:  Dig Dis Sci       Date:  2000-10       Impact factor: 3.199

4.  Evidence of a systemic phenomenon for oxidative stress in cholestatic liver disease.

Authors:  P Ljubuncic; Z Tanne; A Bomzon
Journal:  Gut       Date:  2000-11       Impact factor: 23.059

5.  Abnormal lipid composition of microsomes from cirrhotic rat liver--does it contribute to decreased microsomal function?

Authors:  J Reichen; J T Buters; Z Sojcic; F J Roos
Journal:  Experientia       Date:  1992-05-15

6.  Delta 5 desaturase activity in rat kidney microsomes.

Authors:  C E Irazú; S González-Rodríguez; R R Brenner
Journal:  Mol Cell Biochem       Date:  1993-12-08       Impact factor: 3.396

7.  Do rat kidney cortex microsomes possess the enzymatic machinery to desaturate and chain elongate fatty acyl-CoA derivatives?

Authors:  S K Suneja; M N Nagi; L Cook; P Osei; D L Cinti
Journal:  Lipids       Date:  1991-05       Impact factor: 1.880

8.  Fatty acids homeostasis during fasting predicts protection from chemotherapy toxicity.

Authors:  Marta Barradas; Adrián Plaza; Gonzalo Colmenarejo; Iolanda Lázaro; Luis Filipe Costa-Machado; Roberto Martín-Hernández; Victor Micó; José Luis López-Aceituno; Jesús Herranz; Cristina Pantoja; Hector Tejero; Alberto Diaz-Ruiz; Fatima Al-Shahrour; Lidia Daimiel; Viviana Loria-Kohen; Ana Ramirez de Molina; Alejo Efeyan; Manuel Serrano; Oscar J Pozo; Aleix Sala-Vila; Pablo J Fernandez-Marcos
Journal:  Nat Commun       Date:  2022-09-27       Impact factor: 17.694

9.  Modulation of the mevalonate pathway and cell growth by pravastatin and d-limonene in a human hepatoma cell line (Hep G2).

Authors:  S Kawata; T Nagase; E Yamasaki; H Ishiguro; Y Matsuzawa
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

10.  Effect of pravastatin, a potent 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, on survival of AH130 hepatoma-bearing rats.

Authors:  S Kawata; H Kakimoto; H Ishiguro; E Yamasaki; Y Inui; Y Matsuzawa
Journal:  Jpn J Cancer Res       Date:  1992-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.